SynthesisAntonie van Leeuwenhoek2025
Impact of COVID-19 on the prevalence of multi-drug-resistant bacteria: a literature review and meta-analysis.
Synthesis in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Five years of wastewater surveillance reveal COVID-19-Associated amplification and seasonal shifts inOne health (Amsterdam, Netherlands) · 2026Article
- Bacterial etiology, antimicrobial susceptibility, and clinical outcomes in cervicofacial space infections before, during, and after the COVID-19 pandemic: a 10-year single-centre study.BMC infectious diseases · 2026Article
- Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.JAC-antimicrobial resistance · 2026Article
- Evaluation of Antibiotic Use in Patients Admitted to a Hungarian Intensive Care Unit with Pneumonia and Sepsis: Retrospective Observational Before-After Study.Antibiotics (Basel, Switzerland) · 2026Article
- The Evolving Triad of Carbapenem Resistance: Emergence of Dominant CRPA, Persistent CRAB, and Rebounding CRKP in a Chinese Regional Hospital (2020-2024).Infection and drug resistance · 2026Article
- Antimicrobial Resistance in Urinary Tract Infections Among Patients with and Without Renal Comorbidities: A Retrospective Study from Al-Baha, Saudi Arabia.Pathogens (Basel, Switzerland) · 2025Article
- MDR Bacteremia in the Critically Ill During COVID-19: The MARTINI Study.Pathogens (Basel, Switzerland) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic affected the global healthcare delivery system, raising concerns about its influence on antimicrobial resistance (AMR). This systematic review and meta-analysis assessed the impact of the COVID-19 pandemic on the prevalence of MDR bacteria in different healthcare environments. A systematic search was carried out in PubMed-MEDLINE, Embase, Web of Science, BIOSIS, Scopus, and Google Scholar for articles published from December 2019 to January 2024. After screening 77 full-text studies, 28 studies were included in the analysis. The inclusion criteria included original human studies presenting MDR bacteria incidence before and during/after COVID-19 with reference to Carbapenem-resistant Acinetobacter baumannii, Carbapenem-resistant Enterobacteriaceae, Vancomycin Resistant Enterococci, Carbapenem-Resistant Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, and Extended-Spectrum Beta-Lactamase-producing Enterobacteriaceae. The overall odds ratio (OR = 0.91, 95% CI: 0.70-1.17) indicates no significant change in the prevalence of multidrug-resistant (MDR) bacterial infection between the pre-COVID-19 and the COVID-19 period. There was no significant change in the prevalence of MRSA, ESBL, and VRE pre- and post-COVID. However, there was a significant reduction in the prevalence of CR-Ab, CRE, and CRPA pre- and during/after-COVID-19. MDR prevalence was significantly increased in Asia (18%) while it decreased slightly in North America (10.3%), showing variations in antibiotic use. The findings show that COVID-19 has different effects on the prevalence of MDR bacteria across geographical regions and healthcare facilities.
Indexed as
Identifiers
41045404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.